Circulating Omentin-1, Sustained Inflammation and Hyperphosphatemia at the Interface of Subclinical Atherosclerosis in Chronic Kidney Disease Patients on Chronic Renal Replacement Therapy
Abstract
:1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Shoji, T.; Abe, T.; Matsuo, H.; Egusa, G.; Yamasaki, Y.; Kashihara, N.; Shirai, K.; Kashiwagi, A. Chronic kidney disease, dyslipidemia, and atherosclerosis. J. Atheroscler. Thromb. 2012, 19, 299–315. [Google Scholar] [CrossRef] [Green Version]
- Arici, M.; Walls, J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C-reactive protein the missing link? Kidney Int. 2001, 59, 407–414. [Google Scholar] [CrossRef] [Green Version]
- Watanabe, T.; Watanabe-Kominato, K.; Takahashi, Y.; Kojima, M.; Watanabe, R. Adipose Tissue-Derived Omentin-1 Function and Regulation. Compr. Physiol. 2017, 7, 765–781. [Google Scholar] [CrossRef]
- Zhao, A.; Xiao, H.; Zhu, Y.; Liu, S.; Zhang, S.; Yang, Z.; Du, L.; Li, X.; Niu, X.; Wang, C.; et al. Omentin-1: A newly discovered warrior against metabolic related diseases. Expert Opin. Targets 2022, 26, 275–289. [Google Scholar] [CrossRef]
- Bolignano, D.; Dounousi, E.; Presta, P.; Greco, M.; Duni, A.; Crugliano, G.; Pappas, C.; Pappas, E.; Dragone, F.; Lakkas, L.; et al. Circulating Omentin-1 levels and altered iron balance in chronic haemodialysis patients. Clin. Kidney J. 2022, 15, 303–310. [Google Scholar] [CrossRef]
- Kocijancic, M.; Cubranic, Z.; Vujicic, B.; Racki, S.; Dvornik, S.; Zaputovic, L. Soluble intracellular adhesion molecule-1 and omentin-1 as potential biomarkers of subclinical atherosclerosis in hemodialysis patients. Int. Urol. Nephrol. 2016, 48, 1145–1154. [Google Scholar] [CrossRef]
- Kocijancic, M.; Vujicic, B.; Racki, S.; Cubranic, Z.; Zaputovic, L.; Dvornik, S. Serum omentin-1 levels as a possible risk factor of mortality in patients with diabetes on haemodialysis. Diabetes Res. Clin. Pract. 2015, 110, 44–50. [Google Scholar] [CrossRef]
- Johri, A.M.; Nambi, V.; Naqvi, T.Z.; Feinstein, S.B.; Kim, E.S.H.; Park, M.M.; Becher, H.; Sillesen, H. Recommendations for the Assessment of Carotid Arterial Plaque by Ultrasound for the Characterization of Atherosclerosis and Evaluation of Cardiovascular Risk: From the American Society of Echocardiography. J. Am. Soc. Echocardiogr. Off. Publ. Am. Soc. Echocardiogr. 2020, 33, 917–933. [Google Scholar] [CrossRef] [PubMed]
- Tekce, H.; Tekce, B.K.; Aktas, G.; Alcelik, A.; Sengul, E. Serum omentin-1 levels in diabetic and nondiabetic patients with chronic kidney disease. Exp. Clin. Endocrinol. Diabetes 2014, 122, 451–456. [Google Scholar] [CrossRef] [PubMed]
- Sengul, E.; Duygulu, G.; Dindar, S.; Bunul, F. Serum omentin-1, inflammation and carotid atherosclerosis in patients with non-diabetic chronic kidney disease. Ren. Fail 2013, 35, 1089–1093. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Biscetti, F.; Nardella, E.; Rando, M.M.; Cecchini, A.L.; Angelini, F.; Cina, A.; Iezzi, R.; Filipponi, M.; Santoliquido, A.; Pitocco, D.; et al. Association between omentin-1 and major cardiovascular events after lower extremity endovascular revascularization in diabetic patients: A prospective cohort study. Cardiovasc. Diabetol. 2020, 19, 170. [Google Scholar] [CrossRef] [PubMed]
- Xu, T.; Li, Y.; Su, Y.; Zuo, P.; Gao, Z.; Ke, K. Serum omentin-1 and risk of one-year mortality in patients with ischemic stroke. Clin. Chim. Acta 2020, 505, 167–171. [Google Scholar] [CrossRef] [PubMed]
- Yildiz, S.S.; Sahin, I.; Cetinkal, G.; Aksan, G.; Kucuk, S.H.; Keskin, K.; Cetin, S.; Sigirci, S.; Avci, İ.İ.; Kilci, H.; et al. Usefulness of Serum Omentin-1 Levels for the Prediction of Adverse Cardiac Events in Patients with Hypertrophic Cardiomyopathy. Med. Princ. Pract. 2018, 27, 107–114. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liu, R.; Wang, X.; Bu, P. Omentin-1 is associated with carotid atherosclerosis in patients with metabolic syndrome. Diabetes Res. Clin. Pract. 2011, 93, 21–25. [Google Scholar] [CrossRef]
- Nishimura, M.; Morioka, T.; Hayashi, M.; Kakutani, Y.; Yamazaki, Y.; Kurajoh, M.; Mori, K.; Fukumoto, S.; Shioi, A.; Shoji, T.; et al. Plasma omentin levels are inversely associated with atherosclerosis in type 2 diabetes patients with increased plasma adiponectin levels: A cross-sectional study. Cardiovasc. Diabetol. 2019, 18, 167. [Google Scholar] [CrossRef] [Green Version]
- Kadoglou, N.P.E.; Kassimis, G.; Patsourakos, N.; Kanonidis, I.; Valsami, G. Omentin-1 and vaspin serum levels in patients with pre-clinical carotid atherosclerosis and the effect of statin therapy on them. Cytokine 2021, 138, 155364. [Google Scholar] [CrossRef]
- Bai, P.; Abdullah, F.; Lodi, M.; Sarhadi, M.; Dilip, A.; Shahab, S.; Yasir, F.; Jahangir, M. Association Between Coronary Artery Disease and Plasma Omentin-1 Levels. Cureus 2021, 13, e17347. [Google Scholar] [CrossRef]
- Naqvi, T.Z.; Lee, M.S. Carotid intima-media thickness and plaque in cardiovascular risk assessment. JACC Cardiovasc. Imaging 2014, 7, 1025–1038. [Google Scholar] [CrossRef] [Green Version]
- Liefeldt, L.; Budde, K. Risk factors for cardiovascular disease in renal transplant recipients and strategies to minimize risk. Transpl. Int. 2010, 23, 1191–1204. [Google Scholar] [CrossRef]
- Zoccali, C.; Mallamaci, F.; Tripepi, G. Inflammation and atherosclerosis in end-stage renal disease. Blood Purif. 2003, 21, 29–36. [Google Scholar] [CrossRef]
- Valdivielso, J.M.; Rodriguez-Puyol, D.; Pascual, J.; Barrios, C.; Bermudez-Lopez, M.; Sanchez-Nino, M.D.; Perez-Fernandez, M.; Ortiz, A. Atherosclerosis in Chronic Kidney Disease: More, Less, or Just Different? Arter. Thromb. Vasc. Biol. 2019, 39, 1938–1966. [Google Scholar] [CrossRef] [PubMed]
- Rao, S.S.; Hu, Y.; Xie, P.L.; Cao, J.; Wang, Z.X.; Liu, J.H.; Yin, H.; Huang, J.; Tan, Y.J.; Luo, J.; et al. Omentin-1 prevents inflammation-induced osteoporosis by downregulating the pro-inflammatory cytokines. Bone Res. 2018, 6, 9. [Google Scholar] [CrossRef] [PubMed] [Green Version]
All RRT Patients N = 77 | Normal cIMT N = 41 | High cIMT N = 36 | p | |
---|---|---|---|---|
Age (yrs) | 60 ± 14.1 | 57.2 ± 15.1 | 69.3 ± 14.1 | 0.001 |
Males n (%) | 52 (67.5) | 25 (61) | 27 (75) | 0.31 |
HD/Ktx (n) | 37/40 | 19/22 | 18/18 | 0.59 |
BMI (kg/m2) | 26.0 ± 6.4 | 26.3 ± 5.8 | 25.9 ± 5.3 | 0.66 |
Waist-Hip ratio (cm) | 0.93 ± 0.07 | 0.95 ± 0.09 | 0.92 ± 0.16 | 0.19 |
AMI/Angina n (%) | 17 (22) | 10 (24.4) | 7 (19.4) | 0.54 |
Hypertension n (%) | 54 (70.1) | 30 (73.1) | 24 (66.7) | 0.67 |
Heart failure n (%) | 34 (44.1) | 18 (43.9) | 16 (44.4) | 0.87 |
Diabetes n (%) | 21 (27.7) | 8 (19.5) | 13 (36.1) | 0.10 |
Glycemia (mg/dL) | 102.7 ± 26.7 | 99.5 ± 13.2 | 114.3 ± 12.1 | 0.06 |
Hemoglobin (g/dL) | 11.7 ± 2 | 11.8 ± 1.8 | 11.7 ± 1.2 | 0.72 |
SBP (mmHg) | 138.7 ± 21.2 | 135.6 ± 14.6 | 140.1 ± 14.3 | 0.21 |
DBP (mmHg) | 79.5 ± 12.7 | 85.5 ± 11.3 | 72.0 ± 10.8 | 0.001 |
Pulse pressure (mmHg) | 60.4 ± 18.6 | 51.3 ± 11.1 | 67.5 ± 13.6 | 0.009 |
Serum creatinine (mg/dL) | 2.9 [1.3–7.2] | 3.5[1.9–5.8] | 1.9[1.1–8.8] | 0.36 |
Urea (mg/dL) | 94.8 ± 46.1 | 97.3 ± 30.1 | 95[58–110] | 0.38 |
Sodium (mg/dL) | 139.6 ± 6.7 | 138.9 ± 11.4 | 139.3 ± 15.6 | 0.70 |
Potassium (mg/dL) | 4.69 ± 0.67 | 4.05 ± 0.95 | 4.95 ± 0.60 | 0.09 |
Phosphate (mg/dL) | 4.74 ± 1.39 | 4.13 ± 0.85 | 5.48 ± 1.10 | 0.03 |
Calcium (mg/dL) | 9.39 ± 0.79 | 9.48 ± 0.62 | 9.31 ± 0.52 | 0.49 |
Magnesium (mg/dL) | 2.21 ± 0.58 | 2.25 ± 0.45 | 2.16 ± 0.39 | 0.20 |
iPTH (pg/mL) | 179.3[105.5–358] | 95[79.8–188.5] | 304.3[63.5–408] | 0.08 |
nt-proBNP (pg/mL) | 817 [137.7–3320.7] | 525 [107.4–1320.1] | 310 [203.2–4500] | 0.46 |
Uric acid (mg/dL) | 5.75 ± 1.35 | 5.44 ± 1.19 | 5.98 ± 1.45 | 0.33 |
Albumin (g/dL) | 4.22 ± 0.39 | 4.30 ± 0.19 | 3.99 ± 0.31 | 0.07 |
Total Cholesterol (mg/dL) | 167 ± 41.5 | 149.1 ± 29.9 | 216.3 ± 29.5 | 0.001 |
HDL (mg/dL) | 53.2 ± 14.3 | 55.2 ± 12.9 | 51.8 ± 11.1 | 0.12 |
LDL (mg/dL) | 100.2 ± 35.5 | 99.6 ± 33.8 | 103.3 ± 29.5 | 0.07 |
Triglycerides (mg/dL) | 123 [85–168] | 121 [58–206] | 126 [43–199] | 0.49 |
ESR (mm/h) | 18 [9–30] | 12 [8–84] | 38 [20–56] | 0.19 |
hs-CRP (mg/L) | 3.23 [0.21–6.55] | 2.9 [0.21–3.65] | 13.1 [3.23–25.1] | 0.001 |
Fibrinogen (mg/dL) | 366.9 ± 103.2 | 364.4 ± 101.1 | 355 [95.6–422.9] | 0.56 |
Ferritin (mcg/L) | 97 [30–208] | 89.2 [20.6–108.2] | 120.3 [54.1–350.3] | 0.03 |
RBC (n ×103) | 4.26 ± 1.05 | 4.25 ± 0.99 | 4.28 ± 0.78 | 0.69 |
WBC (n ×103) | 6.90 ± 2.08 | 6.80 ± 2.75 | 6.99 ± 3.01 | 0.21 |
PLT (n × 103) | 225.2 ± 86.3 | 229 ± 99.1 | 222.4 ± 58.6 | 0.10 |
cIMT (mm) | 0.78 ± 0.32 | 0.54 ± 0.16 | 1.05 ± 0.21 | <0.001 |
Omentin-1 (ng/mL) | 324 [90.3–770] | 474.9 [197.2–1432.1] | 168.7 [51.1–457.8] | 0.004 |
Univariate Associations | ||
---|---|---|
R | p | |
Total cholesterol | 0.398 | 0.01 |
(log) Omentin-1 | −0.333 | 0.006 |
Age | 0.329 | 0.007 |
(log) hs-CRP | 0.297 | 0.01 |
(log) Ferritin | 0.260 | 0.03 |
Diastolic BP | −0.250 | 0.04 |
Phosphate | 0.225 | 0.04 |
Multivariate Model 1—fully adjusted Multiple R = 0.71, R2 = 51%; p < 0.0001 | ||
β | p | |
(log) Omentin-1 | −0.687 | 0.03 |
Total cholesterol | 0.415 | 0.001 |
Diastolic BP | −0.311 | 0.02 |
Age | 0.247 | 0.02 |
(log) Ferritin | 0.443 | 0.27 |
Phosphate | −0.051 | 0.61 |
(log) hs-CRP | 0.255 | 0.10 |
Multivariate Model 2—excluding Omentin-1 Multiple R = 0.69, R2 = 48%; p < 0.0001 | ||
β | p | |
Total cholesterol | 0.429 | 0.001 |
Age | 0.280 | 0.01 |
(log) hs-CRP | 0.272 | 0.007 |
Diastolic BP | −0.271 | 0.02 |
(log) Ferritin | 0.226 | 0.04 |
Phosphate | 0.190 | 0.04 |
Multivariate Model 3—excluding hs-CRP and Ferritin Multiple R = 0.65, R2 = 42%; p < 0.0001 | ||
β | p | |
Total cholesterol | 0.369 | 0.003 |
Diastolic BP | −0.301 | 0.01 |
Age | 0.296 | 0.009 |
(log) Omentin-1 | −0.289 | 0.02 |
Phosphate | 0.099 | 0.54 |
Multivariate Model 4—excluding hs-CRP, Ferritin and Omentin-1 Multiple R = 0.61, R2 = 37%; p < 0.0001 | ||
β | p | |
Total cholesterol | 0.522 | <0.001 |
Age | 0.280 | 0.01 |
Diastolic BP | −0.265 | 0.03 |
Phosphate | 0.201 | 0.04 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bolignano, D.; Greco, M.; Arcidiacono, V.; Presta, P.; Caglioti, A.; Andreucci, M.; Dragone, F.; Foti, D.P.; Coppolino, G. Circulating Omentin-1, Sustained Inflammation and Hyperphosphatemia at the Interface of Subclinical Atherosclerosis in Chronic Kidney Disease Patients on Chronic Renal Replacement Therapy. Medicina 2022, 58, 890. https://doi.org/10.3390/medicina58070890
Bolignano D, Greco M, Arcidiacono V, Presta P, Caglioti A, Andreucci M, Dragone F, Foti DP, Coppolino G. Circulating Omentin-1, Sustained Inflammation and Hyperphosphatemia at the Interface of Subclinical Atherosclerosis in Chronic Kidney Disease Patients on Chronic Renal Replacement Therapy. Medicina. 2022; 58(7):890. https://doi.org/10.3390/medicina58070890
Chicago/Turabian StyleBolignano, Davide, Marta Greco, Valentina Arcidiacono, Pierangela Presta, Alfredo Caglioti, Michele Andreucci, Francesco Dragone, Daniela Patrizia Foti, and Giuseppe Coppolino. 2022. "Circulating Omentin-1, Sustained Inflammation and Hyperphosphatemia at the Interface of Subclinical Atherosclerosis in Chronic Kidney Disease Patients on Chronic Renal Replacement Therapy" Medicina 58, no. 7: 890. https://doi.org/10.3390/medicina58070890